8. References:
1. Abbas, O., D.D. Miller, and J. Bhawan, Cutaneous malignant
melanoma: update on diagnostic and prognostic biomarkers. Am J
Dermatopathol, 2014. 36 (5): p. 363-79.
2. Brunssen, A., et al., Impact of skin cancer screening and
secondary prevention campaigns on skin cancer incidence and mortality: A
systematic review. J Am Acad Dermatol, 2017. 76 (1): p.
129-139.e10.
3. Prevention, C.f.D.C.a. United States Cancer Statistics:
Incidence of Malignant Melanoma of the Skin—United States,
2009–2018. USCS Data Brief, no 28, 2022.
4. Luke, J.J., et al., Pembrolizumab versus placebo as adjuvant
therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716):
a randomised, double-blind, phase 3 trial. Lancet, 2022.399 (10336): p. 1718-1729.
5. Larkin, J., et al., Adjuvant Nivolumab Versus Ipilimumab in
Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results
From CheckMate 238. Clin Cancer Res, 2023.
6. Poklepovic, A.S. and J.J. Luke, Considering adjuvant therapy
for stage II melanoma. Cancer, 2020. 126 (6): p. 1166-1174.
7. Pavri, S.N., et al., Malignant Melanoma: Beyond the Basics.Plast Reconstr Surg, 2016. 138 (2): p. 330e-340e.
8. Long, G.V., et al., Pembrolizumab versus placebo as adjuvant
therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant
metastasis-free survival results of a multicentre, double-blind,
randomised, phase 3 trial. Lancet Oncol, 2022. 23 (11): p.
1378-1388.
9. Kwok, G., et al., Pembrolizumab (Keytruda). Hum Vaccin
Immunother, 2016. 12 (11): p. 2777-2789.
10. Wu, Z., et al., Establishing a Prognostic Model Based on
Ulceration and Immune Related Genes in Melanoma Patients and
Identification of EIF3B as a Therapeutic Target. Front Immunol, 2022.13 : p. 824946.
11. Niebling, M.G., et al., The prognostic significance of
microsatellites in cutaneous melanoma. Mod Pathol, 2020.33 (7): p. 1369-1379.
12. Tas, F. and K. Erturk, Neurotropism as a prognostic factor in
cutaneous melanoma patients. Neoplasma, 2018. 65 (2): p.
304-308.
13. Thomas, N.E., et al., Tumor-infiltrating lymphocyte grade in
primary melanomas is independently associated with melanoma-specific
survival in the population-based genes, environment and melanoma study.J Clin Oncol, 2013. 31 (33): p. 4252-9.
14. Marchetti, M.A., et al., Performance of Gene Expression
Profile Tests for Prognosis in Patients With Localized Cutaneous
Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol, 2020.156 (9): p. 953-962.
15. Marsavela, G., et al., Detection of clinical progression
through plasma ctDNA in metastatic melanoma patients: a comparison to
radiological progression. Br J Cancer, 2022. 126 (3): p.
401-408.
16. Passarelli, A., et al., Immune system and melanoma biology: a
balance between immunosurveillance and immune escape. Oncotarget, 2017.8 (62): p. 106132-106142.
17. Azimi, F., et al., Tumor-infiltrating lymphocyte grade is an
independent predictor of sentinel lymph node status and survival in
patients with cutaneous melanoma. J Clin Oncol, 2012. 30 (21):
p. 2678-83.
18. Gershenwald, J.E., et al., Melanoma staging: Evidence-based
changes in the American Joint Committee on Cancer eighth edition cancer
staging manual. CA Cancer J Clin, 2017. 67 (6): p. 472-492.
19. Amin, M.B., et al., AJCC cancer staging manual . Vol. 1024.
2017: Springer.
20. Dong, H., et al., Tumor-associated B7-H1 promotes T-cell
apoptosis: a potential mechanism of immune evasion. Nat Med, 2002.8 (8): p. 793-800.
21. Herbst, R.S., et al., Predictive correlates of response to the
anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014.515 (7528): p. 563-567.
22. Tumeh, P.C., et al., PD-1 blockade induces responses by
inhibiting adaptive immune resistance. Nature, 2014.515 (7528): p. 568-571.
23. Spranger, S., et al., Density of immunogenic antigens does not
explain the presence or absence of the T-cell–inflamed tumor
microenvironment in melanoma. Proceedings of the National Academy of
Sciences, 2016. 113 (48): p. E7759-E7768.
24. Yousef, Z., et al., Phase II trial of the IDO pathway
inhibitor indoximod plus pembrolizumab for the treatment of patients
with advanced melanoma. Journal for ImmunoTherapy of Cancer, 2021.9 (6): p. e002057.
25. Brandacher, G., et al., Prognostic value of indoleamine
2,3-dioxygenase expression in colorectal cancer: effect on
tumor-infiltrating T cells. Clin Cancer Res, 2006. 12 (4): p.
1144-51.
26. Huang, S.J., et al., Imiquimod enhances IFN-gamma production
and effector function of T cells infiltrating human squamous cell
carcinomas of the skin. J Invest Dermatol, 2009. 129 (11): p.
2676-85.
27. Pandit, A.S., et al., Using topical imiquimod for the
management of positive in situ margins after melanoma resection. Cancer
Med, 2015. 4 (4): p. 507-12.
28. Wolf, I.H., et al., Treatment of lentigo maligna (melanoma in
situ) with the immune response modifier imiquimod. Arch Dermatol, 2005.141 (4): p. 510-4.
29. Scarfì, F., et al., The role of topical imiquimod in melanoma
cutaneous metastases: A critical review of the literature. Dermatologic
Therapy, 2020. 33 (6): p. e14165.
30. Cheraghlou, S., et al., Association of Treatment Facility
Characteristics With Overall Survival After Mohs Micrographic Surgery
for T1a-T2a Invasive Melanoma. JAMA Dermatol, 2021. 157 (5): p.
531-539.